Article
Consensus guidance on the management of pregnancy in patients with inflammatory bowel disease (IBD) was simultaneously published in six international journals, including The American Journal of Gastroenterology.
All News
Article
Dr. Jack Cush reviews the news, FDA approvals, and journal articles. In this episode: HMGCR Abs, FDA approvals and Cush eats crow.
Article
Analysis of a German psoriatic arthritis (PsA) patients registry demonstrates sex-specific differences regarding clinical manifestation and treatment outcomes, especially with regard to drug discontinuations.
Article
A phase IV trial from Spain demonstrates that optimization of therapy by lessening biological DMARDs in rheumatoid arthritis (RA) may be feasible, with a low risk of flare.
Article
A study of radiographic outcomes in difficult-to-treat rheumatoid arthritis (D2T RA) and poly-refractory RA (pr-RA) show a subset in whom damage is rapid and in need of more aggressive therapy.
Article
Dr. Jack Cush reviews the news, journal reports and important associations in rheumatology from the past week on RheumNow.com.
Article
FDA announced yesterday that guselkumab (Tremfya) is approved for use in pediatric patients moderate to severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA) in children six years and older (weighing at least 40 kg).
Dr. John Cush
Tweet
Tramadol not effective at chronic pain
The strong opioid painkiller, tramadol, is not that effective at easing chronic pain for which it’s widely prescribed, finds a pooled data analysis of the available research, published online in BMJ Evidence Based Medicine. https://t.co/zFWwyy1j3O
Dr. John Cush
Tweet
FDA has approved nerandomilast (PDE4b inhibitor) for treatment of adults with idiopathic pulmonary fibrosis (IPF). Approval is based on 2 RCTs, FIBRONEER-IPF & FIBRONEER-ILD, that show slowing of lung function decline IP & progressive pulmonary fibrosis (PPF) pts. https://t.co/pIQwyLUBoj
Dr. John Cush
Tweet
Taiwan study of HBV or HCV reactivation w/ bDMARD use in PsO & PsA - among 5527 treatment episodes (3197 ts/bDMARDs) found a 10% risk of reactivation of HBVr (10.6%) & HCV (9.9%), highest w/ TNFi. Reactivation assoc w/ TNFi, HBsAg+, HBeAg+, immunosuppressant use without antiviral https://t.co/AwpmRpfJUT
Dr. John Cush
Tweet
NY Times on Osteoporosis in Men
The NY Times has addressed the problem of osteoporosis in men noting a need for increased awareness and screening...
Read more: https://t.co/SzNtuPllY6 https://t.co/13EcEfv4ab
Dr. John Cush
Tweet
HMGCR Abs is assoc w/ necrotizing myopathy. Review of 78 pts w/ HMGCR IMNM. 31 had overlap w/ higher MMT-score, less muscle weakness, more ILD, arthralgia, wt loss & rash. 12 had musc. dystrophy like dz w/ earlier onset, longer duration, less myalgia & extramuscular Sxs https://t.co/RpzZI0zI7E
Dr. John Cush
Tweet
Retrospective study of 42 adult Still' pts Rx after 2010 w/ IL‐1 inhib if given < 6 mos (early) or > 6mos of Sxs. Early IL-1i had more inactive dz (CID)(67% vs 38%; P = 0.17) & steroid d/c w/in 6 mos. 10 major flares observed (62% after IL‐1i suspension or spacing) https://t.co/uD1meQuYvj
Dr. John Cush
Tweet
Not all difficult-to-treat RA will have rapid radiographic progression
A study of radiographic outcomes in difficult-to-treat rheumatoid arthritis (D2T RA) and poly-refractory RA (pr-RA) show a subset in whom damage is rapid and in need of more aggressive therapy. https://t.co/WrwyeW5qsj
Dr. John Cush
Tweet
Prospective study of 62 lupus nephritis pts rx w/ induction therapy - MMF vs IV CYC x 6 mos followed by MMF for next 6 mos. At 1 year complete renal remission (CRR) seen in 77% MMF vs 29% CYC. https://t.co/wG2Qrn1PSU https://t.co/gP8XYO4q92
Dr. John Cush
Tweet
FDA Approves Deuruxolitinib for use in adult patients with moderate to severe Alopecia Areata https://t.co/D6KXtDjfHL https://t.co/2WSIBWNexX
Dr. John Cush
Tweet
Impact cumulative MTX on liver fibrosis? 1314 #PsA pts (age 44), 28% on MTX. Total of 44 (3%) had baseline liver fibrosis & 12% developed it over med/ 5.6 yrs. Cumulative MTX Did NOT assoc w/ liver fibrosis (OR 0.99), but high BMI & DM did (Metabolic factors) https://t.co/OSVZHskjB4
Dr. John Cush
Tweet
RA at risk for pneumonia & hospitalisation. Pop/ study (41187 RA vs 205935 matched controls). w/ 4yrs F/U, RA had signif. more pneumonia (adj HR 1.73) & hospitaliz (aHR 2.26); higher w/ seropositives (aHR 1.86 & 2.52) & bDMARDs (1.73), but not tsDMARDs (0.93) https://t.co/XJE1FqVqCn
Dr. John Cush
Tweet
Polypharmacy Impairs Rheumatoid Arthritis Outcomes
A French early rheumatoid arthritis (RA) study has shown that polypharmacy (PP) was associated with significantly lower treatment responses and more serious adverse events (SAEs).
https://t.co/QAJYzHEaFv https://t.co/vUeBsLCYNE
Dr. John Cush
Tweet
Scleroderma-associated Interstitial Lung Disease
Since the first placebo-controlled randomized trial published nearly 20 years ago for the treatment of patients with SSc-ILD, evaluating cyclophosphamide vs. placebo, there have been several other randomized studies to guide the https://t.co/n8S0N2wTqu
